✨
AI Summary
- Atacicept stabilized kidney function in IgA nephropathy patients over 104 weeks.
- Phase 3 trial showed a significantly lower risk of kidney disease progression.
- Mean eGFR change was -0.1 mL/min/1.73 m² with atacicept vs -5.7 with placebo.
Guests on This Episode
SN
Sayna Norouzi
2 podcast appearances